Lancet Global Health
Sep 2019 Volume 7Number 9e1147-e1286
Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis
Voluntary licences are increasingly being used to expand access to patented essential medicines in low-income and middle-income countries (LMICs). Since 2014, non-exclusive voluntary licences have been issued by Gilead and Bristol-Myers Squibb for key drugs for hepatitis C virus (HCV) infection. We aimed to evaluate the effect of these licences on access to HCV treatment…Voluntary licensing initiatives appear to substantially improve HCV treatment uptake in eligible countries. This evidence supports the expansion of licensing strategies to include more countries and more treatments.
Bryony Simmons, Graham S Cooke, Marisa Miraldo